ArticleCancer chemotherapy and pharmacology2018

Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.

Ulrike Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.